Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 4, 2009, Pages 342-347

  Demanes, D Jeffrey ^a   Brandt, David ^a   Schour, Lionel ^a   Hill, Dennis R ^a  

^a California Endocurietherapy Cancer Center   (United States)

Author keywords

Androgen deprivation therapy; External beam radiation therapy; HDR brachytherapy; High dose rate brachytherapy; Prostate carcinoma

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CAUSE SPECIFIC SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTCOME VARIABLE; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROSTATE; PROSTATE CANCER; RADIATION DOSE; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG RESISTANCE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROBABILITY; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; REFERENCE VALUES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 69349100578     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31818cd277     Document Type: Article

References (34)

1. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097-1105. (Pubitemid 34787842)
2. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233-1239. (Pubitemid 41352111)
3. Peeters ST, Heemsbergen WD, Koper PCM, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24:1990-1996. (Pubitemid 46622106)
4. Grimm PD, Blasko JC, Sylvester JE, et al. 10-year biochemical (prostatespecific antigen) control of prostate cancer with 125I brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:31-40.
5. Potters L, Morgenstern C, Calugaru E, et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2005;173:1562-1566. (Pubitemid 40524771)
6. Stock RG, Stone NN, Cesaretti JA, et al. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and post treatment biopsy results. Int J Radiat Oncol Biol Phys. 2006;64:527-533.
7. Sylvester J, Grimm P, Blasko J, et al. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys. 2007;67:57-64. (Pubitemid 44959493)
8. Galalae RM, Martinez AA, Mate T, et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:1048-1055. (Pubitemid 38314785)
9. Demanes DJ, Rodriguez RR, Schour L, et al. High-Dose-Rate intensity modulated brachytherapy with external beam radiotherapy for prostate cancer: California Endocurietherapy's 10 year results. Int J Radiat Oncol Biol Phys. 2005;61:1306-1316. (Pubitemid 40470411)
10. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet. 2002;360:103-108. (Pubitemid 34786197)
11. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate cancer - long term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61:1285-1290. (Pubitemid 40470408)
12. Hanks GE, Pajak TF, Porter A, et al. Phase III Trial of long term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protcol 92-02. J Clin Oncol. 2003;21:3972-3978. (Pubitemid 46606211)
13. Potters L, Torre A, Ashley R, et al. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol. 2000;18:1187-1192. (Pubitemid 30159835)
14. Beyer DC, McKeough T, Thomas T, et al. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005;61:1299-1305. (Pubitemid 40470410)
15. Sylvester J, Blasko J, Grimm P, et al. Impact of short-course androgen ablation on the biochemical progression-free survival of high-risk prostate cancer patients managed with permanent brachytherapy. J Brachyther Int. 2001;17:173-180. (Pubitemid 33108504)
16. Lee L, Stock RG, Stone NN, et al. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys. 2002;52:444-452. (Pubitemid 34170849)
17. Merrick GS, Butler WM, Wallner KE, et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005;61:32-43.
18. Galalae RM, Martinez AA, Mate T, et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:1048-1055. (Pubitemid 38314785)
19. Demanes DJ, Rodriguez RR, Altieri GA. High dose rate brachytherapy: the California Endocurietherapy (CET) Method. Radiother Oncol. 2000;57:289-296. (Pubitemid 30943111)
20. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111-1116. (Pubitemid 34787844)
21. Zelefsky MJ, Marion C, Fuks Z, et al. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy. J Urol. 2003;170:1828-1832. (Pubitemid 37254937)
22. Kupelian P, Kuban D, Thanes H, et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys. 2005;61:415-419.
23. Martinez AA, Gustafson G, Gonzalez J, et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:316-327. (Pubitemid 34522097)
24. Pilepich MV, Winter K, Madhu JJ, et al. Phase III Radiation Therapy Oncology Group Trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243-1252. (Pubitemid 32727802)
25. D'Amico AV, Manola J, Loffredo M, et al. 6-Month Androgen Suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292:821-827. (Pubitemid 39079668)
26. Horwitz EM, Winter K, Hanks GE, et al. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advance non metastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2001;49:947-956. (Pubitemid 32184601)
27. Roach M, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression (RTOG 94-13). J Clin Oncol. 2003;21:1904-1911. (Pubitemid 46606377)
28. Lawton CA, DeSilvio M, Roach M, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/ radiation interactions. Int J Radiat Oncol Biol Phys. 2007;69:646-655. (Pubitemid 47418390)
29. Zelefsky MJ, Yoshiya Y, Kollmeier MA, et al. Long Term Outcome Following 3D Conformal/Intensity Modulated External Beam Radiotherapy for Clinical Stage T3 Prostate Cancer. Eur J Urol. In Press.
30. Martinez AA, Demanes JD, Galalae R, et al. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Int J Radiat Oncol Biol Phys. 2005;62:1322-1331. (Pubitemid 40982050)
31. Vargus CA, Galalae R, Demanes J, et al. Lack of benefit of pelvic irradiation in prostate cancer with high risk of positive lymph nodes treated with high dose radiation. Int J Radiat Oncol Biol Phys. 2005;63:1474-1482. (Pubitemid 41628045)
32. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25:2420-2425. (Pubitemid 46999213)
33. Keating NL, O'Malley AJ, Smith MR, et al. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448-4456. (Pubitemid 46630983)
34. Sharifi N, Gulley JL, Dahut WL, et al. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238-244. (Pubitemid 41043794)